Overview

Surgical or Radiotherapeutic Intervention Concerning Large Singular Stable to Progressive Metastases in Patients With BRAFV600-mutated Melanoma Receiving Treatment With Encorafenib + Binimetinib

Status:
NOT_YET_RECRUITING

Trial end date:
2030-08-01

Target enrollment:

Participant gender:

Summary

This is an open-label, prospective, single arm study conducted in Germany to investigate local treatment (i.e. surgery or radiotherapy or electrochemotherapy) of metastases showing no response to encorafenib (E) + binimetinib (B) combination therapy and continuation of EB therapy afterwards. The purpose of this study is to determine PFS of individual patients treated with local intervention while continuing therapy with EB.

Phase:

PHASE4

Details

Lead Sponsor:

SRH Wald-Klinikum Gera GmbH

Collaborator:

Pierre Fabre Pharma GmbH

Treatments:

binimetinib
encorafenib